Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
VYBRIQUE (SILDENAFIL CITRATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
VYBRIQUE
NDA
Get alerts
SILDENAFIL CITRATE | N210858 | IBSA INSTITUT BIOCHIMIQUE SA
4 strengths
1 unique patent
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
1 unique patent, 1 exclusivity by expiration date
All strengths
EQ 25MG BASE
EQ 50MG BASE
EQ 75MG BASE
EQ 100MG BASE
Active (1)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
2034
Today
11123287
Dec. 16, 2033
NP
Dec. 16, 2028
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 25MG BASE
RLD
1 patent
1 exclusivity
▴
FILM;ORAL | Approved: Dec 16, 2025
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
11123287
Dec 16, 2033
—
—
Yes
—
—
Exclusivities (1)
Code
Date
Status
NP
Dec 16, 2028
Active
#002 — EQ 50MG BASE
RLD
1 patent
1 exclusivity
▾
FILM;ORAL | Approved: Dec 16, 2025
#003 — EQ 75MG BASE
RLD
1 patent
1 exclusivity
▾
FILM;ORAL | Approved: Dec 16, 2025
#004 — EQ 100MG BASE
RLD
1 patent
1 exclusivity
▾
FILM;ORAL | Approved: Dec 16, 2025